Exploration of inhibitory mechanisms of curcumin in lung cancer metastasis using a miRNA- transcription factor-target gene network

De-min Jiao, Li Yan, Li-shan Wang, Hui-zhen Hu, Xia-li Tang, Jun Chen, Jian Wang, You Li, Qing-yong Chen*

1 Department of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, P.R. China, 2 Department of Oncology, The 117th Hospital of PLA, Hangzhou, Zhejiang, P.R. China, 3 Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, P.R. China

‡ These authors are co-first authors on this work.
* cnyong117@163.com

Abstract

The present study was aimed to unravel the inhibitory mechanisms of curcumin for lung cancer metastasis via constructing a miRNA-transcription factor (TF)-target gene network. Differentially expressed miRNAs between human high-metastatic non-small cell lung cancer 95D cells treated with and without curcumin were identified using a TaqMan human miRNA array followed by real-time PCR, out of which, the top 6 miRNAs (miR-302b-3p, miR-335-5p, miR-338-3p, miR-34c-5p, miR-29c-3p and miR-34a-35p) with more verified target genes and TFs as confirmed by a literature review were selected for further analysis. The miRecords database was utilized to predict the target genes of these 6 miRNAs, TFs of which were identified based on the TRANSFAC database. The findings of the above procedure were used to construct a miRNA-TF-target gene network, among which miR-34a-5p, miR-34c-5p and miR-302b-3p seemed to regulate CCND1, WNT1 and MYC to be involved in Wnt signaling pathway through the LEF1 transcription factor. Therefore, we suggest miR-34a-5p/miR-34c-5p/miR-302b-3p—LEF1—CCND1/WNT1/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin.

Introduction

Lung cancer, predominantly non-small-cell lung cancer (NSCLC), is the most common cause of cancer mortality in the United States, with an estimated 158,080 cancer deaths occurred in 2016 [1]. Metastatic progression is the main factor to result in the poor prognosis of patients [2]. Exploration of strategies to inhibit metastasis has justifiably attracted enormous attention in clinic.
Curcumin, a natural polyphenol derived from turmeric (Curcuma longa), is one of the most widely investigated compounds recently due to its protective property against cancer [3, 4]. Curcumin may suppress the invasion and metastasis of lung cancer cells by downregulating the expression of matrix metalloproteinases, which can be mediated by protein kinase Ca (PKCα) / NADPH oxidase-2 (Nox-2) / reactive oxygen species (ROS) / activating transcription factor-2 (ATF-2) [5] or glucose transporter 1 (GLUT1) / membrane type 1-MMP (MT1-MMP) [6]. Furthermore, evidence is also provided to indicate the inactivation of Wnt/β-catenin pathway in the therapeutic process of curcumin [7]. However, the inhibitory mechanisms of curcumin in lung cancer metastasis remain under investigation.

A consensus has been reached that gene expression can be regulated by microRNAs (miRNAs) via binding to its 3’ untranslated regions [8]. Thus, we hypothesize curcumin may regulate its target gene expression by controlling miRNAs, thus affecting lung cancer metastasis. This hypothesis has been demonstrated by recent studies as follows: Jin et al. report that curcumin may inhibit proliferation and promote apoptosis of NSCLC cells via upregulation of miR-192-5p followed by inhibition of PI3K/Akt pathway [9]. The study of Ye et al. highlights the pro-apoptotic effects of curcumin depend on induction of miR-192-5p/215 followed by targeting X-linked inhibitor of apoptosis (XIAP) gene [10]. Nevertheless, the research on the miRNAs that were changed after curcumin treatment remains limited and rare studies focused on miRNAs associated with lung cancer metastasis.

The goal of this study was to screen crucial miRNAs that were differentially expressed in high-metastatic NSCLC cells undergoing curcumin treatment or not by the use of a miRNA microarray analysis. The target genes of miRNAs and their function were also predicted. The findings of our study may further unearth the inhibitory mechanisms of curcumin in lung cancer metastasis and provide new therapeutic targets for lung cancer.

Materials and methods

Reagents and cell culture

Curcumin was purchased from Sigma Chemical Company (St Louis, MO, USA). A 100 mM stock solution of curcumin was prepared in dimethyl sulfoxide (Sigma, St Louis, MO, USA) and stored at—20˚C.

Human high-metastatic NSCLC 95D cell line was obtained from the Cell Bank at the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (HyClone, Logan, Utah, USA), 100 units/mL penicillin and streptomycin at 37˚C in 5% CO₂.

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay

Cell viability was measured by MTT assay following the instructions of the manufacturer. Briefly, cells were seeded on 96-well plates (Corning Incorporation, Corning, NY, USA) at a density of 5 × 10³ cells/well and grown overnight. The absorption was determined at 570 nm using an automated plate reader (Shenzhen Procan Electronics Incorporation, Rayto, Shenzhen, China). Each experimental condition was performed in triplicate.

Wound healing assay

The 95D cells were seeded into a six-well plate and grown to confluence. Wound was created by scraping confluent cell monolayers with a 10 μL pipette tip. The cells treated with different concentrations of curcumin (0 μM, 10 μM or 20 μM) were allowed to migrate for 24 h. At 0 h
and 24 h after scratching, images were taken under an inverted microscope (Olympus IX71, Olympus, China, × 40). The gap distance was measured by the Image J software (National Institute of Mental Health, Bethesda, MD, USA). Migration rate = gap distance (24 h) / gap distance (0 h).

Cell invasion assay

Invasion assay was carried out using modified matrigel boyden chambers which consisted of a 24-well Millicell (Millipore Corporation, Shanghai, China) membrane filter (8 μm pore size) as described previously [11]. Matrigel was diluted to 200 μg/mL with cold distilled water and applied to the top side of filter. Briefly, cells were trypsinized and resuspended in serum-free medium. A total of 10⁵ cells were added to the upper chamber of each well. The bottom chambers were filled with 500 μL RPMI 1640 medium supplemented with 10% FBS and different concentrations of curcumin (10 or 20 μM). The chamber was incubated for 24 h at 37˚C. At the end of incubation, cells located on the upper surface of the membrane were carefully removed with a cotton swab. Cells invading through the matrigel to the lower surface of the membrane were fixed with methanol and stained with 0.5% crystal violet. The invading cells on the lower surface of the membrane filter were counted under a light microscope (Puzhe PhotoElectric Company, Leica, Shenzhen, China). The data presented were the average number of cells attached to the bottom surface from five random fields. Each experiment was carried out in triplicate.

miRNAs assay

Differentially expressed miRNAs between 95D cell samples treated with or without 10 μM curcumin, were identified based on the platform: TaqMan Array Human MicroRNA A+B Card Set v3 (Life Technologies, Carlsbad, California, USA) and real-time analysis of 770 human miRNAs (Sanger miRBase v18) using a 7900HT RT-PCR System (Life Technologies, Carlsbad, California, USA), with fold change (FC) > 2.0 or < 0.05 and p-value < 0.05 as the cutoff point.

Out of these identified differentially expressed miRNAs, the top six miRNAs with more verified target genes and TFs than other miRNAs in lung cancer review literatures were selected for further analysis. Subsequently, the experimentally verified target genes of the 6 miRNAs were identified using miRecords database (http://miRecords.umn.edu/miRecords) which is an integrated resource containing 1135 validated miRNA-target interactions in seven animal species [12]. Furthermore, TFs were screened out from the experimentally verified target genes according to the TRANSFAC database (http://www.gene-regulation.com/cgi-bin/pub/databases/transfac/) [13].

In addition, all potential target genes of the 6 miRNAs with biological complexity (BC) > 6 were also predicted according to miRecords database to further analyze how the 6 selected miRNAs played roles in the inhibition of NSCLC by curcumin. Similarly, TFs were screened from the predicted target genes and the targets genes of the screened TFs were determined based on the TRANSFAC database. Eventually, a miRNA-TF-target gene network was constructed using The Search Tool for the Retrieval of Interacting Genes (STRING) [14] and visualized by Cytoscape software (http://www.cytoscape.org/) [15].

Gene ontology and Kyoto encyclopedia of genes and genomes pathway enrichment analysis

Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses were performed for the experimentally verified target genes of the selected 6 miRNAs and network genes using The Database for Annotation, Visualization and Integrated
Discovery (DAVID) tool (http://david.abcc.ncifcrf.gov). Bonferroni adjusted p-value < 0.05 and false discovery rate (FDR) < 0.05 were chosen as cut-off criterion for GO and KEGG analyses.

**Protein-protein interaction network construction**

A protein-protein interactions (PPI) network was built with the target genes of the 6 miRNAs using STRING software [16] to analyze the interactions between these target genes. The PPIs with scores > 0.4 was included in the PPI network.

**Results**

**Effect of curcumin on 95D cell viability**

Cell viability of the control group (0 μM curcumin) was designated as 100% in our study. As shown in Fig 1, cell viability was insignificantly decreased in response to 10 μM curcumin treatment for 24 h. However, it was decreased to 49% in cells exposed to 20 μM curcumin compared with the control group (p < 0.01). The viability of 95D cells on exposure to 40 μM curcumin was further reduced.

**Effect of curcumin on 95D cell migration and invasion**

Based on the cell viability results, the concentrations of 10 μM and 20 μM were chosen to determine the effect of curcumin on 95D cells migration and invasion. The results indicated both 10 μM and 20 μM could significantly repress 95D cells migration (Fig 2A and 2B, p < 0.01) and invasion (Fig 2C and 2D, p < 0.01). Notably, 10 μM curcumin inhibited cell migration and invasion obviously, but did not result in a significant reduction in cell viability, suggesting that 10 μM would be a suitable concentration to unravel the molecular mechanisms underlying the anti-tumor metastasis action of curcumin.

**Identification of crucial differentially expressed miRNAs and their experimentally validated target genes and TFs**

Totally, 36 differentially expressed miRNAs were identified between 95D cells treated with and without curcumin (FC > 2.0 or < 0.05 and p < 0.05, Table 1). Further, 6 miRNAs (miR-302b-3p, miR-335-5p, miR-338-3p, miR-34c-5p, miR-29c-3p and miR-34a-35p) with more verified target genes and TFs than others in lung cancer review literatures were screened, suggesting these 6 miRNAs might play critical roles in the suppression of lung cancer metastasis by curcumin. Based on the miRecords database, 39 experimentally verified target genes of these 6 miRNAs were identified (Table 2), of which three genes were recognized as TFs based on TRANSFAC database, including E2F transcription factor 3 (E2F3), v-myb avian myelocytomatosis viral oncogene homolog (MYB) and v-myc avian myelocytomatosis viral oncogene homolog (MYC).

Function enrichment analysis showed that these 39 verified target genes were mainly involved in 10 significant GO terms (Table 3) and 4 significant KEGG pathways (Table 4). The most significant term was regulation of cell proliferation (Bonferroni adjusted p-value = 8.66E-05, FDR = 1.34E-04), with 13 genes enriched, such as E2F3, MYC, NOTCH1, NOTCH2, cyclin-dependent kinase 6 (CDK6), B-cell lymphoma 2 (BCL2) and cyclin-D1 (CCND1). Besides, the terms of epithelium, epidermis and ectoderm development may be associated with cell migration, with NOTCH1, mitogen-activated protein 2 kinase 1 (MAP2K1) and BCL2 enriched. The identified KEGG pathways were all related with cancer development (pathways in cancer,
focal adhesion, small cell lung cancer and pancreatic cancer) and migration (focal adhesion), with CCND1 enriched in all pathways.

Construction of an miRNA-TF-target gene network using crucial miRNAs

Totally, 353 miRNA-target gene pairs of the above 6 miRNAs (BC > 6) were predicted based on the miRecords database. Out of these target genes, E2F3, hepatic leukemia factor (HLF), lymphoid enhancer binding factor 1 (LEF1), neurofibromin 1a (NF1A), interferon regulatory factor 2 (IRF2), contactin 2 (CNTN2), E74-like factor 2 (ELF2), MYC and MYC associated factor X (MAX) were found to be TFs based on the TRANSFAC database. Using these data, a miRNA-TF-target gene network was constructed, including 5 miRNAs, 9 TFs and 55 downstream target genes of the TFs (Fig 3). miR-34a-5p, miR-34c-5p and miR-302b can regulate the target gene CCND1, Wnt family member 1 (WNT1) and MYC via the LEF1 transcription factor (Fig 3). The miR-338 was excluded from the network, because it only had one target gene, ubiquitin-conjugating enzyme E2Q family member 1 (UBE2Q1).

Function enrichment analysis showed that the above 64 genes significantly participated in 14 GO terms (Table 3) and 3 KEGG pathways (Table 4), among which Wnt signaling pathway was the common result in these two analyses, suggesting this pathway may be of particular importance in lung cancer metastasis and curcumin treatment. Several genes, including Wnt family member 1 (WNT1), CCND1, MYC, LEF1, transcription factor 7 like 1 (TCF7L1) and catenin beta 1 (CTNNB1) were enriched, indicating they may be important therapeutic targets for lung cancer.

PPI network

The interactions of the above 64 genes were also investigated by establishing a PPI network (Fig 4), which consisted of 31 nodes (protein) and 93 edges (PPIs). After calculating the degree
of each gene (the number of edges adjacent to each node), both MYC and CCND1 were suggested to be hub genes in the PPI network, with the highest degree of 14.

Discussion

The present study identified 36 differentially expressed miRNAs between 95D cells treated with or without curcumin, 6 of which were chosen to be further investigated. By comprehensively analyzing the experimentally validated and all potential target genes of these 6 miRNAs, our study suggested miR-34a-5p, miR-34c-5p and miR-302b-3p seemed to be particularly important in inhibition of lung cancer metastasis by curcumin because their target genes (e.g. CCND1, WNT1, MYC and LEF1) were significantly enriched in metastasis related pathways (Wnt signaling pathway and Focal adhesion). As a transcription factor, LEF1 also could regulate CCND1, WNT1 and MYC. Therefore, we believe miR-34a-5p/miR-34c-5p/miR-302b-3p...
—LEF1—CCND1/WNT1/MYC axis may be a crucial mechanism in inhibition of lung cancer metastasis by curcumin. This conclusion seemed to be indirectly demonstrated by reviewing the literatures.

Several studies have reported that miR-34a may act as a tumor suppressor gene, with a downregulated expression in various tumor types, including lung cancer [17]. Delivery of miR-34a into cancer cells or animal models could promote cell proliferation, invasion and metastasis, which was mediated by targeted inhibition of its target genes, including CD44 [18] and MMPs (e.g. MMP9, MMP14, MMP2) [19, 20]. In addition, miR-34 was also demonstrated to regulate the TFs followed by the target genes of TFs. For example, Geng et al. confirmed miR-34a could reduce the viability and invasion of cervical cancer cells through the following mechanism:

Table 1. The 36 differentially expressed miRNAs between curcumin-treated group and control group.

| miRBase-human-18th | Target sequence | Fold change |
|-------------------|----------------|-------------|
| hsa-miR-330-3p    | UCUCUGGCUGGUGCUUAGGC | 142.34 |
| hsa-miR-331-5p    | UGUGUAGGGUCGUCAUUCC | 70.74 |
| hsa-miR-1276      | UAAAGGGCCUGUGGAGAGCA | 45.97 |
| hsa-miR-544a      | AUUCUGAUUUUAUGAAGGUU | 15.27 |
| hsa-miR-29c-5p    | UGACCAGAUUCCGUGUGUUC | 10.96 |
| hsa-miR-335-5p    | UCAAGGACCAGAUAAGGAAAGGU | 10.09 |
| hsa-miR-296-5p    | GAGGGUGUGGGAGGCCUCUC | 8.59 |
| hsa-miR-34a-5p    | UGGCGAGUGCUUAGGUGGUUG | 7.26 |
| hsa-miR-26a-1-3p  | CCUAUUGGGUUACUGGACG | 6.63 |
| hsa-miR-190a      | UGAUUGGUUUGUAUUGUUG | 4.66 |
| hsa-miR-362-3p    | AACACUACAGGGUGACCUU | 4.52 |
| hsa-let-7f-3p     | CUUIACACGGUCAUCUGCUUCC | 4.26 |
| hsa-miR-302b-3p   | UAAGUGCUCUCAUGGUUUAUGAG | 3.34 |
| hsa-miR-338-3p    | UCCAGCAUCAGUGAAUUGUGUG | 2.86 |
| hsa-miR-455-3p    | GCAGUCCAGGGCUAUAACAG | 2.17 |
| hsa-miR-29c-5p    | UAGCAGACUUGGAACUGGUUA | 0.49 |
| hsa-miR-154-3p    | AAUCUACAGCGUGACGUU | 0.48 |
| hsa-miR-21-3p     | CAACACAGGCGAGAUGGCUU | 0.45 |
| hsa-miR-377-5p    | AGAGAGUGGCUCUGGUAAUC | 0.43 |
| hsa-miR-34c-5p    | AGGCAGUGUAGUAGGUGAGU | 0.37 |
| hsa-miR-1257      | AGUGAAUGGGGUUUGUGGACC | 0.31 |
| hsa-miR-744-3p    | CUGUIUGCACUAACUCAACCU | 0.31 |
| hsa-miR-502-5p    | AUCUUCUGUCAUCUGGGGCUUA | 0.27 |
| hsa-miR-33a-3p    | CAAUGUUUCACAGUGCAUCAC | 0.23 |
| hsa-miR-424-3p    | CAAACUGGAGGCGUCUGCAU | 0.21 |
| hsa-miR-92a-1-5p  | AGGUUGGAGCUGGUUUCAAUGCU | 0.17 |
| hsa-miR-10b-3p    | ACAGAUUGGAUUCUGGGGAAU | 0.15 |
| hsa-miR-769-3p    | CUGGGAGUCGCCGGUGUGCUU | 0.06 |
| hsa-miR-1179      | AAGCAUUCUCUCAUGUGUUGG | 0.05 |
| hsa-miR-516a-3p   | UGCUCUCCUUCAGAGGGU | 0.05 |
| hsa-miR-148a-5p   | AAAGGUCUGAGACACUCGCACU | 0.05 |
| hsa-miR-604       | AGGCGUGGAAUUCAGGAC | 0.04 |
| hsa-miR-499a-5p   | UUAAGACCUUGCAUGUAGGUU | 0.04 |
| hsa-miR-1262      | UGGGGUAUUUGUAGAAAGGAU | 0.04 |
| hsa-let-7a-3p     | CUUACAAUUCUACGUGUCUCUC | 0.03 |
| hsa-miR-25-5p     | AGGCGGAGACUUGGGCAUUG | 0.005 |

doi:10.1371/journal.pone.0172470.t001
downregulating E2F3 which then inhibited the expression of survivin [21]. Liang et al. firstly demonstrated a negative relationship between miR-34a and LEF1 expression by luciferase assays and further verified that miR-34a suppressed the migration and invasion of prostate cancer cells through increasing E-cadherin and decreasing N-cadherin in a LEF1-dependent manner [22]. In this study, we also found an important regulation relationship between miR-34a and LEF1, which has not been studied in lung cancer cells previously. Furthermore, existing evidence suggests that LEF1 is a crucial transcription factor to mediate Wnt/β-catenin signaling and participate in tumor progression [23, 24]. Thus, the expressions of Wnt signaling related genes (CCND1, WNT1 and MYC) may be regulated by LEF1 [25, 26], which was also demonstrated in our study. Also, elevated expressions of CCND1 [27], WNT1 [28] and MYC [29] were shown to be associated with malignant characters of lung cancer, leading to an unfavorable prognosis. Accordingly, we have reasons to trust that miR-34a (downregulated)—LEF1 (upregulated)—CCND1/WNT 1/MYC (upregulated) axis may be an important target for inhibition of lung cancer metastasis and to upregulate miR-34a may be an underlying strategy to achieve this goal. As expected, our study showed miR-34a was significantly upregulated by curcumin (FC = 7.26), which was in line with previous studies in other cancers [30, 31].

miR-302b also seems to be a potential molecular marker for cancer invasion and metastasis [32]. miR-302b is downregulated in hepatocellular carcinoma cancer specimens and overexpression of miR-302b suppresses invasion and metastasis by directly targeting Akt2 followed by regulation of NF-κB and MMP-2 in human hepatocellular carcinoma cells [33]. Similarly, miR-302b was found to be significantly lowly expressed in high-metastatic lung cancer cell line 95D than that in low metastatic cell line 95C. Transfection of miR-302b exerts anti-proliferation and anti-migration effects on 95D cells, which was accompanied with significantly down-regulated expression of TGFβRII, phosphorylated ERK1/2 and MMP9 induced by TGF-β1 [34]. However, the inhibitory mechanism of miR-302b on cancer remains unclear and its regulation on transcription factor is rarely reported [35]. In this study, we first found miR-302b might be involved in lung cancer metastasis by regulating LEF1 followed by Wnt signaling related genes, which need a further experiment confirmation. Although growing evidence has indicated that upregulation of miR-302b may be an important mechanism during cancer treatments [36], whether the expression of miR-302b can be changed after curcumin seems not to be investigated. We first demonstrated miR-302b was significantly upregulated

### Table 2. The verified target genes of the 6 miRNAs.

| miRNA        | Genes count | Validated target genes                                                                 |
|--------------|-------------|----------------------------------------------------------------------------------------|
| hsa-miR-302b-3p | 3           | CCND1, LEFTY1, LEFTY2                                                                  |
| hsa-miR-335-5p | 0           | ——                                                     |  |
| hsa-miR-338-3p | 1           | UBE2Q1                                                                                                |
| hsa-miR-34c-5p | 1           | MYC                                                                                          |
| hsa-miR-29c-5p | 14          | LAMC1, DNMT3A, DNMT3B, COL3A1, COL4A1, COL3A1, COL15A1, TDG, FUSIP1, COL1A1, COL1A2, COL4A2, FBN1, FIK3R1, CDC42, |
| hsa-miR-34a-5p | 20          | DLL1, NOTCH1, BCL2, E2F3, CDK6, VEGFA, MYCN, NOTCH2, SIRT1, CCND1, MYB, MYC, Notch-1, JAG1, MET, MAP2K1, AXIN2, WNT1, CD44, Axl, EphA5 |

Note: 0 and —— represent none of the validated target genes have been discovered.

doi:10.1371/journal.pone.0172470.t002
(FC = 3.34) when treatment with 10 μM curcumin, which also needs a further experiment confirmation.

As a member of miR-34 conserved family, miR-34c plays a similar role with miR-34a theoretically. However, in our study, we found miR-34c was significantly downregulated

---

**Table 3. Gene Ontology (GO) term enrichment analysis.**

| Category ID | Term                                      | Genes                                                                 | Bonferroni adjusted p-value | FDR         |
|-------------|-------------------------------------------|-----------------------------------------------------------------------|----------------------------|-------------|
| A GO:0042127 | Regulation of cell proliferation          | E2F3, CDK6, JAG1, SIRT1, LEFTY1, MYCN, NOTCH2, NOTCH1, CCND1, BCL2, VEGFA, AXIN2, MYC | 8.66E-05                  | 1.34E-04    |
| GO:0001709  | Cell fate determination                   | CDC42, WNT1, NOTCH2, DLL1, JAG1                                       | 1.23 E-03                  | 1.90E-03    |
| GO:0045165  | Cell fate commitment                      | CDC42, WNT1, NOTCH2, NOTCH1, BCL2, DLL1, JAG1                         | 1.90 E-03                  | 2.94E-03    |
| GO:0060429  | Epithelium development                    | NOTCH2, NOTCH1, COL4A1, CD44, MAP2K1, BCL2, VEGFA, JAG1                | 3.49E-03                  | 5.41E-03    |
| GO:0008544  | Epidermis development                     | NOTCH1, MAP2K1, BCL2, COL3A1, COL1A2, COL1A1                          | 8.14E-03                  | 1.27E-02    |
| GO:0007398  | Ectoderm development                      | NOTCH1, MAP2K1, BCL2, COL3A1, COL1A2, COL1A1                          | 1.22E-02                  | 1.91E-02    |
| GO:0045596  | Negative regulation of cell differentiation| CCND1, NOTCH1, DLL1, CDK6, JAG1, AXIN2, SIRT1                         | 2.05E-02                  | 3.20E-02    |
| GO:0030182  | Neuron differentiation                    | CDC42, WNT1, NOTCH1, CD44, MAP2K1, BCL2, VEGFA, DLL1, JAG1            | 2.39E-02                  | 3.74E-02    |
| GO:0048730  | Epidermis morphogenesis                    | NOTCH1, BCL2, COL1A2, COL1A1                                         | 2.78E-02                  | 4.36E-02    |
| GO:0048729  | Tissue morphogenesis                      | NOTCH2, NOTCH1, CD44, BCL2, COL1A2, JAG1, COL1A1                      | 3.00E-02                  | 4.70E-02    |
| B GO:0030097 | Hemopoiesis                               | LMO2, LYN, TP53, DLL1, RAG2, RUNX1, TCF3, ADA, CTNNB1, CD1D, TIMP1     | 3.67E-05                  | 5.11E-05    |
| GO:0016055  | Wnt receptor signaling pathway            | WNT1, CCND1, MITF, TLE4, LEF1, TLE1, MARK4, TCF7L1, CTNNB1             | 6.74E-05                  | 9.39E-05    |
| GO:0048534  | Hemopoietic or lymphoid organ development  | LMO2, LYN, TP53, DLL1, RAG2, RUNX1, TCF3, ADA, CTNNB1, CD1D, TIMP1     | 9.14E-05                  | 1.27E-04    |
| GO:0002520  | Immune system development                 | LMO2, LYN, TP53, DLL1, RAG2, RUNX1, TCF3, ADA, CTNNB1, CD1D, TIMP1     | 1.60E-04                  | 2.22E-04    |
| GO:0042127  | Regulation of cell proliferation          | ODC1, E2F3, LYN, BECN1, MITF, TP53, MMP7, MARK4, ADA, TIMP1, CTNNB1, CCND1, IFNB1, TCF3, MYC, PLAU | 4.00E-04                  | 5.56E-04    |
| GO:0045893  | Positive regulation of transcription, DNA-dependent | WNT1, E2F3, MITF, TP53, LEF1, RUNX1, ALX4, TCF3, MYC, TCF7L1, TP73, CTNNB1 | 3.16E-03                  | 4.41E-03    |
| GO:0051254  | Positive regulation of RNA metabolic process | WNT1, E2F3, MITF, TP53, LEF1, RUNX1, ALX4, TCF3, MYC, TCF7L1, TP73, CTNNB1 | 3.43E-03                  | 4.78E-03    |
| GO:0045941  | Positive regulation of transcription      | WNT1, E2F3, MITF, TP53, LEF1, RUNX1, ALX4, TCF3, MYC, TCF7L1, TP73, CTNNB1 | 1.55E-02                  | 2.17E-02    |
| GO:0010628  | Positive regulation of gene expression    | WNT1, E2F3, MITF, TP53, LEF1, RUNX1, ALX4, TCF3, MYC, TCF7L1, TP73, CTNNB1 | 2.04E-02                  | 2.89E-02    |
| GO:0045165  | Cell fate commitment                      | WNT1, MITF, TP53, DLL1, RAG2, TCF3, CTNNB1                            | 2.31E-02                  | 3.26E-02    |
| GO:0009952  | Anterior/posterior pattern formation       | WNT1, HOXC13, LEF1, DLL1, ALX4, TCF7L1, CTNNB1                        | 2.41E-02                  | 3.39E-02    |
| GO:0006357  | Regulation of transcription from RNA polymerase II promoter | ELF2, MITF, TP53, LEF1, TLE1, SNAI2, TCF7L1, CTNNB1, IRF2, ALX4, RUNX1, MYC, TCF3 | 3.12E-02                  | 4.42E-02    |

FDR, false discovery rate; A, pathway enrichment analysis of the verified target genes of miRNAs; B, pathway enrichment analysis of genes in the miRNAs-transcription factors-target genes network.

doi:10.1371/journal.pone.0172470.t003
(FC = 0.37) after treatment with 10 μM curcumin, indicating miR-34c may be a proto-oncogene. This conclusion seemed to be supported by a recent study which indicated forced expression of miR-34c may contribute to resistance to caspase-8-induced apoptosis in lung cancer cells [37]. Nevertheless, it is essential to further explore how miR-34c, miR-34a and miR-302b collectively to regulate LEF1 followed by Wnt signaling related genes in lung cancer [38].

Table 4. Pathway enrichment analysis.

| Pathway ID | Term                        | Genes                                                                 | Bonferroni adjusted p-value | FDR       |
|------------|-----------------------------|----------------------------------------------------------------------|-----------------------------|-----------|
| A          | hsa05200 Pathways in cancer | E2F3, COL4A1, MAP2K1, MET, CDK6, WNT1, CDC42, CCND1, BCL2, VEGFA, LAMC1, AXIN2, MYC | 1.93E-06                  | 3.11E-05  |
|            | hsa04510 Focal adhesion      | CDC42, CCND1, COL4A1, MAP2K1, BCL2, MET, VEGFA, COL3A1, COL1A2, LAMC1, COL1A1 | 2.20E-06                  | 3.54E-05  |
|            | hsa05222 Small cell lung cancer | E2F3, CCND1, COL4A1, BCL2, CDK6, LAMC1, MYC                                | 2.40E-04                  | 3.90E-03  |
|            | hsa05212 Pancreatic cancer   | CDC42, E2F3, CCND1, MAP2K1, VEGFA, CDK6                                     | 2.30E-04                  | 3.20E-04  |
| B          | hsa05216 Thyroid cancer      | CCND1, TP53, LEF1, MYC, TCF7L1, CTNNB1                                      | 1.28E-04                  | 1.91E-03  |
|            | hsa04310 Wnt signaling pathway | WNT1, CCND1, CSNK1E, MMP7, TP53, LEF1, MYC, TCF7L1, CTNNB1                  | 7.95E-04                  | 1.19E-02  |
|            | hsa05213 Endometrial cancer  | CCND1, TP53, LEF1, MYC, TCF7L1, CTNNB1                                     | 2.46E-03                  | 3.69E-02  |

FDR, false discovery rate; A, pathway enrichment analysis of the verified target genes of miRNAs; B, pathway enrichment analysis of genes in the miRNAs-transcription factors-target genes network.

doi:10.1371/journal.pone.0172470.t004

Fig 3. The miRNA-TF-target gene network. The red, yellow and green nodes represent the miRNAs, TFs and target genes of TFs, respectively. The arrows stand for regulatory relationship between two nodes. The TFs in rhombus nodes and their target genes are enriched in the Wnt signaling pathway, and the circle nodes represent the genes in uncertain signaling pathways.

doi:10.1371/journal.pone.0172470.g003
Although a great amount of documentary evidence has indicated its anti-carcinogenesis properties, extensively bringing curcumin to the clinic remains a difficult process because of poor oral bioavailability due to low absorption [39]. Recently, scholars have attempted to encapsulate or incorporate curcumin in nanoparticles to enhance curcumin delivery [39]. As expected, concentration of curcumin was increased in mice via i.p. after loaded with solid lipid nanoparticles (SLN). Furthermore, SLN-curcumin enhanced the targeting of curcumin to lung and tumor, finally improving the inhibition efficiency of curcumin to 69.3% from 19.5% [40]. However, other strategies [(such combination of curcumin and its target miRNAs (miR-34a and miR-302b) mimics)] to enhance the therapeutic effects are needed to be further investigated.

Conclusions

Our present study provides some novel, underlying mechanisms of curcumin (miR-34a-5p/miR-34c-5p/miR-302b-3p—LEF1—CCND1/WNT1/MYC axis) on lung cancer metastasis. Further in vitro and in vivo experimental studies were necessary to confirm these findings and explore combination strategies to enhance the therapeutic efficiency of curcumin.

Author Contributions

Conceptualization: DMJ LY QYC.

Data curation: DMJ LY LSW HZH XLT JC JW YL.

Formal analysis: DMJ LY LSW HZH XLT JC JW YL.
Funding acquisition: DMJ QYC.
Investigation: DMJ LY LSW HZH XLT JC JW YL.
Methodology: DMJ LY LSW.
Project administration: DMJ LY QYC.
Resources: DMJ LY QYC.
Software: LSW.
Supervision: DMJ LY QYC.
Validation: DMJ LY HZH XLT JC.
Visualization: DMJ LY LSW.
Writing – original draft: DMJ LY QYC.
Writing – review & editing: DMJ LY QYC.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. Ca A Cancer Journal for Clinicians. 2016; 66(1):7–30. doi: 10.3322/caac.21332 PMID: 26742998
2. Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung JY, Yen CJ, et al. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer. 2015; 88(2):187–94. doi: 10.1016/j.lungcan.2015.02.012 PMID: 25747806
3. Killian PH, Kronski E, Michalik KM, Barbieri O, Astigiano S, Sommerhoff CP, et al. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis. 2012; 33(12):2507–19. doi: 10.1093/carcin/bgs312 PMID: 23042094
4. Da W, Zhu J, Wang L, Sun Q. Curcumin suppresses lymphatic vessel density in an in vivo human gastric cancer model. Tumor Biology. 2015; 36(7):5215–23. doi: 10.1007/s13277-015-3178-8 PMID: 25874494
5. Fan Z, Duan X, Cai H, Wang L, Li M, Qu J, et al. Curcumin inhibits the invasion of lung cancer cells by modulating the PKCα/Nox-2/ROS/ATF-2/MMP-9 signaling pathway. Oncology Reports. 2015; 34(2):691–8. doi: 10.3892/or.2015.4044 PMID: 26059056
6. Liao H, Wang Z, Deng Z, Ren H, Li X. Curcumin inhibits lung cancer invasion and metastasis by attenuating GLUT1/MT1-MMP/MMP2 pathway. International Journal of Clinical & Experimental Medicine. 2015; 8(6):8948–57.
7. Lu Y, Wei C, Xi Z. Curcumin suppresses proliferation and invasion in non-small cell lung cancer by modulation of MTA1-mediated Wnt/β-catenin pathway. In Vitro Cellular & Developmental Biology—Animal. 2014; 50(9):840–50.
8. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nature Reviews Genetics. 2007; 8(2):93–103. doi: 10.1038/nrg1990 PMID: 17230196
9. Jin H, Qiao F, Wang Y, Xu Y, Shang Y. Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway. Oncology Reports. 2015; 34(5):2782–9. doi: 10.3892/or.2015.4258 PMID: 26351877
10. Ye M, Zhang J, Miao Q, Yao L. Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. Cancer Letters. 2015; 357(1):196–205. doi: 10.1016/j.canlet.2014.11.028 PMID: 25444916
11. Ji C, Cao C, Lu S, Kivrin R, Amaral A, Kouttab N, et al. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemotherapy and Pharmacology. 2008; 62(5):857–65. doi: 10.1007/s00280-007-0674-6 PMID: 18214481
12. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA–target interactions. Nucleic Acids Research. 2009; 37(Database issue):D105–10. doi: 10.1093/nar/gkn851 PMID: 18996891
13. Wingender E. The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. Briefings in Bioinformatics. 2008; 9(4):326–32. doi: 10.1093/bib/bbn016 PMID: 18436575

14. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Research. 2013; 41(D1):D808–15.

15. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research. 2003; 13(11):2498–504. doi: 10.1101/gr.1239303 PMID: 14597658

16. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Research. 2011; 39(Database issue):D561–8. doi: 10.1093/nar/gkq973 PMID: 21045058

17. Basak SK, Veena MS, Oh S, Lai C, Vangala S, Elashoff D, et al. The CD44(high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression. Plos One. 2013; 8(9):e73195. doi: 10.1371/journal.pone.0073195 PMID: 24019906

18. Zhao H, Ma B, Wang Y, Han T, Zheng L, Sun C, et al. miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. Oncology Reports. 2013; 29(3):1027–36. doi: 10.3892/or.2013.2234 PMID: 23314380

19. Jia LF, Wei SB, Mitchelson K, Gao Y, Zheng YF, Meng Z, et al. miR-34a Inhibits Migration and Invasion of Tongue Squamous Cell Carcinoma via Targeting MMP9 and MMP14. Plos One. 2014; 9(9):e108435. doi: 10.1371/journal.pone.0108435 PMID: 25288950

20. Nie J, Ge X, Geng Y, Cao H, Zhu W, Jiao Y, et al. miR-34a inhibits the migration and invasion of esophageal squamous cell carcinoma by targeting Yin Yang-1. Oncology Reports. 2015; 34(1):311–7. doi: 10.3892/or.2015.3962 PMID: 25954903

21. Geng D, Song X, Ning F, Song Q, Yin H. MiR-34a Inhibits Viability and Invasion of Human Papillomavirus-Positive Cervical Cancer Cells by Targeting E2F3 and Regulating Survivin. International Journal of Gynecological Cancer. 2015; 25(4):707–13. doi: 10.1097/GIC.0000000000000399 PMID: 25675046

22. Liang J, Li Y, Daniels G, Stanos K, De Marzo A, Wei J, et al. LEF1 Targeting EMT in Prostate Cancer Invasion is Regulated by miR-34a. Molecular Cancer Research. 2015; 13(4):681–8. doi: 10.1158/1541-7786.MCR-14-0503 PMID: 25357085

23. Murakami T, Toda S, Fujimoto M, Ohtsuki M, Byers HR, Etoh T, et al. Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochemical & Biophysical Research Communications. 2001; 288(1):8–15.

24. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 2009; 138(1):51–62. doi: 10.1016/j.cell.2009.04.030 PMID: 19576624

25. Lei B, Chai W, Wang Z, Liu R. Highly expressed UNC119 promotes hepatocellular carcinoma cell proliferation through Wnt/beta-catenin signaling and predicts a poor prognosis. American Journal of Cancer Research. 2015; 5(10):3123–34. PMID: 26693064

26. Watson AL, Rahmann EP, Moriarity BS, Choi K, Conboy CB, Greeley AD, et al. Canonical Wnt/beta-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance. Cancer Discovery. 2013; 3(6):674–89. doi: 10.1158/2159-8290.CD-13-0081 PMID: 23353903

27. Dragoj M, Milsic S, Bankovic J, Dinic J, Pesic M, Tanic N, et al. Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients’ outcome. Tumor Biology. 2015; 36(11):8773–80. doi: 10.1007/s13277-015-3620-y PMID: 26055143

28. Nakashima T, Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, et al. Wnt1 overexpression associated with tumor proliferation and a poor prognosis in non-small cell lung cancer patients. Oncology Reports 2008; 19(1):203–9. PMID: 18097996

29. Zhang E, Li W, Yin D, De W, Zhu L, Sun S, et al. c-Myc-regulated long non-coding RNA H19 indicates a poor prognosis and affects cell proliferation in non-small-cell lung cancer. Tumor Biology. 2016; 37(3):4007–15. doi: 10.1007/s13277-015-4185-5 PMID: 26482621

30. Guo J, Li W, Shi H, Xie X, Li L, Tang H, et al. Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Molecular and Cellular Biochemistry. 2015; 382(1–2):103–11. doi: 10.1007/s11010-015-1723-6 PMID: 23771315

31. Toden S, Okugawa Y, Buhmann C, Nattama D, Anguiano E, Baldwin N, et al. Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer. Cancer Prevention Research. 2015; 8(5):431–43. doi: 10.1158/1940-6207.CAPR-14-0354 PMID: 25712055
32. Zhang M, Yang Q, Zhang L, Zhou S, Ye W, Yao Q, et al. miR-302b is a potential molecular marker of esophageal squamous cell carcinoma and functions as a tumor suppressor by targeting ErbB4. Journal of Experimental & Clinical Cancer Research. 2014; 33:10.

33. Wang L, Yao J, Sun H, Sun R, Chang S, Yang Y, et al. miR-302b suppresses cell invasion and metastasis by directly targeting AKT2 in human hepatocellular carcinoma cells. Tumor Biology. 2016; 37(1):847–55. doi: 10.1007/s13277-015-3330-5 PMID: 26254095

34. Li J, Yu J, Zhang H, Wang B, Guo H, Bai J, et al. Exosomes-Derived MiR-302b Suppresses Lung Cancer Cell Proliferation and Migration via TGFβRII Inhibition. Cellular Physiology & Biochemistry. 2016; 38(5):1715–26.

35. Chen PH, Shih CM, Chang WC, Cheng CH, Lin CW, Ho KH, et al. MicroRNA-302b-inhibited E2F3 transcription factor is related to all trans retinoic acid-induced glioma cell apoptosis. Journal of Neurochemistry. 2014; 131(6):731–42. doi: 10.1111/jnc.12820 PMID: 25040912

36. Zhang Y, Hu H, Song L, Cai L, Wei R, Jin W. Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation. Toxicology Letters. 2013; 222(1):1–9. doi: 10.1016/j.toxlet.2013.06.242 PMID: 23845851

37. Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene. 2012; 32(3):341–51. doi: 10.1038/onc.2012.51 PMID: 22370637

38. Xu M, Jin H, Xu CX, Bi WZ, Wang Y. MiR-34c inhibits osteosarcoma metastasis and chemoresistance. Medical Oncology. 2014; 31(6):972. doi: 10.1007/s12032-014-0972-x PMID: 24802328

39. Mahran RI, Hagras M, Sun D, Brenner D. Bringing Curcumin to the Clinic in Cancer Prevention: a Review of Strategies to Enhance Bioavailability and Efficacy. Aaps Journal. 2017; 19(1):54–81. doi: 10.1208/s12248-016-0003-2 PMID: 27783266

40. Wang P, Zhang L, Peng H, Li Y, Xiong J, Xu Z. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. Materials Science & Engineering C Materials for Biological Applications. 2013; 33(8):4802–8.